GlaxoSmithKline Pharmaceuticals Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: GLAXO BSE: 500660

₹2732.80

Oct. 5, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #18 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	427,010	143.5	13.7%	7.6%	—	72	8	30
Divi's Laboratories Limited	244,125	83.0	15.3%	57.8%	0.33%	70	4	51
Torrent Pharmaceuticals Limited	161,506	77.7	12.2%	35.3%	0.80%	56	0	31
Zydus Lifesciences Limited	113,616	32.6	17.3%	14.5%	0.09%	74	24	84
Cipla Limited	107,888	35.1	11.2%	-11.7%	0.97%	73	29	62
Laurus Labs Limited	106,505	122.0	17.1%	128.4%	—	78	24	53
Mankind Pharma Limited	102,382	46.9	11.7%	0.9%	—	68	12	86
Dr. Reddy's Laboratories Limited	100,411	150.9	10.9%	-3.7%	—	62	33	71
GlaxoSmithKline Pharmaceuticals Limited (this stock)	46,295	43.8	45.3%	0.0%	2.09%	99	0	31

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹45,229 Cr

EV / EBITDA

30.0x

EV / Sales

11.57x

Market cap / Sales

11.84x

Earnings yield

2.29%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 986 Cr, up 16.2% YoY.

↑ Positive

Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 253 Cr, up 23.8% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	924	338	253	₹14.9500
March 31, 2026	989	369	275	₹16.2300
Dec. 31, 2025	1,023	378	277	₹16.3600
Sept. 30, 2025	974	351	255	₹14.9200
June 30, 2025	805	279	205	₹12.0800
March 31, 2025	966	355	260	₹15.3500
Dec. 31, 2024	946	306	229	₹
Sept. 30, 2024	1,000	339	249	₹14.4500
June 30, 2024	811	248	182	₹10.7200
March 31, 2024	911	269	193	₹11.3900
Dec. 31, 2023	805	65	45	₹9.8800
Sept. 30, 2023	953	297	216	₹12.7200
June 30, 2023	738	179	131	₹6.9400

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23
Total income (before exceptional items)	986	1,025	1,054	1,005	849	1,006	1,032	847	941	833	982	775	810
Operating revenue	924	989	1,023	974	805	966	1,000	811	911	805	953	738	782
Other income	62	36	32	31	44	39	32	36	30	28	28	37	28
Operating expenses	631	642	655	639	554	635	681	582	656	587	667	597	615
Operating profit	293	347	368	335	251	331	319	229	255	218	287	141	167
Operating profit margin	31.7%	35.1%	35.9%	34.4%	31.2%	34.2%	31.9%	28.3%	28.0%	27.0%	30.1%	19.1%	21.3%
Depreciation	16	13	20	17	16	15	17	16	18	17	18	16	17
Interest	1	1	1	1	0	1	0	0	1	0	0	0	1
Exceptional items, gain / (loss)	—	—	—	3	—	—	5	—	2	-163	—	17	10
Profit before tax	338	369	378	351	279	355	339	248	269	65	297	179	187
Tax	85	94	101	96	74	95	90	67	76	20	81	48	56
Net profit	253	275	277	255	205	260	249	182	193	45	216	131	131
EPS	14.95	16.23	16.36	14.92	12.08	15.35	14.45	10.72	11.39	9.88	12.72	6.94	7.77
Net profit (TTM)	1,060	1,012	997	969	895	884	669	636	585	523	642	620	—
EPS (TTM)	62.46	59.59	58.71	56.80	52.60	51.91	46.44	44.71	40.93	37.31	37.11	35.81	35.70

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	3,790	1,376	1,012
March 31, 2025	3,723	1,248	919
March 31, 2024	3,407	809	585
March 31, 2023	3,216	832	608

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	5.8%	3.5%	3,933^†	—	3,531^†	3,318^†	3,441^†	3,304^†	3,302^†	3,230^†	2,949^†	3,066^†
Operating revenue	5.6%	3.5%	3,790	3,723	3,407	3,216	3,365^†	3,194^†	3,225^†	3,129^†	2,896^†	2,995^†
Other income	—	—	143^†	—	123^†	102^†	76^†	110^†	78^†	101^†	54^†	72^†
Operating expenses	—	—	2,490^†	—	2,507^†	2,417^†	2,570^†	2,499^†	2,566^†	2,522^†	—	—
Operating profit	17.6%	13.3%	1,300^†	—	901^†	799^†	795^†	695^†	658^†	606^†	—	—
Operating profit margin	—	—	34.3%^†	—	26.4%^†	24.9%^†	23.6%^†	21.8%^†	20.4%^†	19.4%^†	—	—
Depreciation	—	—	66^†	—	70^†	66^†	69^†	79^†	83^†	49^†	38^†	26^†
Interest	—	—	3^†	—	2^†	2^†	2^†	4^†	6^†	1^†	—	—
Exceptional items, gain / (loss)	—	—	3^†	—	-144^†	-1^†	12^†	-173^†	-324^†	5^†	18^†	46^†
Profit before tax	18.2%	20.1%	1,376	1,248	809	832	812^†	550^†	322^†	664^†	542^†	511^†
Tax	—	—	364^†	—	224^†	228^†	408^†	192^†	212^†	238^†	190^†	174^†
Net profit	18.5%	23.1%	1,012	919	585	608	—	358^†	110^†	425^†	352^†	337^†
EPS	18.6%	23.1%	59.59^†	—	40.93^†	35.70^†	23.89^†	21.11^†	6.50^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	34.3%^†	—	26.4%^†	24.9%^†	23.6%^†	21.8%^†	20.4%^†	19.4%^†	—	—
EBIT margin	36.4%^†	—	23.8%^†	25.9%^†	24.2%^†	17.3%^†	10.2%^†	21.2%^†	—	—
PBT margin	36.3%	33.5%	23.7%	25.9%	24.1%^†	17.2%^†	10.0%^†	21.2%^†	18.7%^†	17.1%^†
Net margin	26.7%	24.7%	17.2%	18.9%	—	11.2%^†	3.4%^†	13.6%^†	12.2%^†	11.2%^†
Interest coverage	505.11x^†	—	450.47x^†	460.88x^†	409.26x^†	156.73x^†	51.87x^†	1207.75x^†	—	—
Dividend payout	70.5%^†	—	78.2%^†	84.0%^†	125.6%^†	94.7%^†	307.7%^†	—	—	—
Earnings retention	29.5%^†	—	21.8%^†	16.0%^†	-25.6%^†	5.3%^†	-207.7%^†	—	—	—
Current ratio	2.12x	1.88x	—	—	—	—	—	—	—	—
Quick ratio	1.87x	1.64x	—	—	—	—	—	—	—	—
Debt to equity	0.00x	0.00x	—	—	—	—	—	—	—	—
Return on equity	45.1%	47.1%	—	—	—	—	—	—	—	—
Return on assets	23.7%	22.4%	—	—	—	—	—	—	—	—
Return on capital employed	54.8%^†	—	—	—	—	—	—	—	—	—
Asset turnover	0.89x	0.91x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	881	385	-737	55	826
March 31, 2025	1,280	-37	-769	23	1,257
March 31, 2024	579	15	-561	31	548
March 31, 2023	488	805	-1,544	44	444
March 31, 2022	820	-420	-524	35	785

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	4,275	2,241	2,072	0	0	3,722	1,757	1,066	274	430
March 31, 2025	4,101	1,949	1,780	0	0	3,576	1,901	536	270	463
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.